Timothy J. Schroeder, Founder and CEO of CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization will present at two industry meetings this week. He will present at the Bourne Partners 9th Annual Global Healthcare Executive Summit and the Alliance for Regenerative Medicine (ARM) Cell & Gene Meeting on the Mesa on October 1 and October 2, respectively.
The Bourne Partners 9th annual Global Healthcare Executive Summit will be held in Charlotte, NC on October 1. Tim will present a featured case study to the attendees titled, "Establishing a World Class CRO." The presentation will focus on lessons learned from CTI's 20 years of success. Bourne Partners is a financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors focusing on facilitating the efficient movement of capital through the global healthcare sector.
The ARM Meeting on the Mesa will be held in Carlsbad, California from October 2-4. On October 2, Tim will chair a session at the meeting titled, "Cell and Gene Therapy for Neurological Product Indications." The session will focus on the state of development and clinical progress for these next-generation durable treatments for CNS conditions. ARM is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. In addition to speaking at the event, CTI, a team of industry-recognized experts in regenerative medicine, is also a sponsor and regular supporter of ARM and its various meetings.
"We're honored to be a part of both the Bourne Partners Summit and the Meeting on the Mesa," remarks Schroeder. "We are happy to share our experience and lessons learned from the past 20 years in the hopes that we can both help support our peers and further efforts in breakthroughs using cell and gene therapies."
Timothy Schroeder, CEO and Founder of CTI, has over 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm, which in one of the 20 largest CROs in the world and has supported more than 100 drug and device approvals, currently works on behalf of approximately 135 global pharmaceutical and biotechnology companies. Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Tim is currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. Tim was named as an EY Entrepreneur of the Year in 2015, as Top Leader by the Enquirer Media in 2016, and as Deal Maker of the Year in 2017 by the Association for Corporate Growth.